Discovering and developing new medicines for malaria control and elimination

Infectious Disorders - Drug Targets

Volumn 13, Issue 4, 2013, Pages 292-302

  Wells, Timothy N C ^a  

^a ICC   (Switzerland)

Author keywords

Antimalarials; Clinical pipeline; Drug discovery; Malaria; Malaria eradication; Screening

Indexed keywords

ALBITIAZOLIUM BROMIDE; AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARCO; ARTEMETHER PLUS BENFLUMETOL; ARTEMISONE; ARTESUN; ARTESUNATE PLUS PYRONARIDINE; ARTIMIST; AZITHROMYCIN PLUS CHLOROQUINE; COARSUCAM; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; FERROQUINE; FOSMIDOMYCIN; GNF 156; GNF 179; KAE 609; KAF 156; MEFLOQUINE; NAPHTHOQUINONE; NITD 609; OZ 439; PIPERAQUINE; SYNRIAM; TAFENOQUINE; UNCLASSIFIED DRUG; WINTHROP;

ARTICLE; DISEASE TRANSMISSION; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; PATIENT COMPLIANCE; PLASMODIUM VIVAX MALARIA; SCREENING; VACCINATION;

ANIMALS; ANTIMALARIALS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; MALARIA;

EID: 84893433759     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526513666131129160156     Document Type: Article

References (55)

1. Olliaro, P.; Wells, T. N. The global portfolio of new antimalarial medicines under development. Clin Pharmacol. Ther., 2009, 85(6), 584-595.
2. Anthony, M. P.; Burrows, J. N.; Duparc, S.; Moehrle, J. J.; Wells, T. N. The global pipeline of new medicines for the control and elimination of malaria. Malar J., 2012, 7(11), 316-341.
3. Alonso, P. L.; Brown, G.; Arevalo-Herrera, M.; Binka, F.; Chitnis, C.; Collins, F.; Doumbo, O. K.; Greenwood, B.; Hall, B. F.; Levine, M. M.; Mendis, K.; Newman, R. D.; Plowe, C. V.; Rodriguez, M. H.; Sinden, R.; Slutsker, L.; Tanner, M. A research agenda to underpin malaria eradication. PLoS. Med., 2011, 8(1), e1000406.
4. Wells, T. N. Microbiology. Is the tide turning for new malaria medicines? Science, 2010, 329(5996), 1153-1154.
5. Plouffe, D.; Brinker, A.; McNamara, C.; Henson, K.; Kato, N.; Kuhen, K.; Nagle, A.; Adrian, F.; Matzen, J. T.; Anderson, P.; Nam, T. G.; Gray, N. S.; Chatterjee, A.; Janes, J.; Yan, S. F.; Trager, R.; Caldwell, J. S.; Schultz, P. G.; Zhou, Y.; Winzeler, E. A. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl. Acad. Sci. USA, 2008, 105(26), 9059-9064.
6. Guiguemde, W. A.; Shelat, A. A.; Bouck, D.; Duffy, S.; Crowther, G. J.; Davis, P. H.; Smithson, D. C.; Connelly, M.; Clark, J.; Zhu, F.; Jimenez-Diaz, M. B.; Martinez, M. S.; Wilson, E. B.; Tripathi, A. K.; Gut, J.; Sharlow, E. R.; Bathurst, I.; El, M. F.; Fowble, J. W.; Forquer, I.; McGinley, P. L.; Castro, S.; Angulo-Barturen, I.; Ferrer, S.; Rosenthal, P. J.; Derisi, J. L.; Sullivan, D. J.; Lazo, J. S.; Roos, D. S.; Riscoe, M. K.; Phillips, M. A.; Rathod, P. K.; Van Voorhis, W. C.; Avery, V. M.; Guy, R. K. Chemical genetics of Plasmodium falciparum. Nature, 2010, 465(7296), 311-315.
7. Gamo, F. J.; Sanz, L. M.; Vidal, J.; De, C. C.; Alvarez, E.; Lavandera, J. L.; Vanderwall, D. E.; Green, D. V.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; Cardon, L. R.; Garcia-Bustos, J. F. Thousands of chemical starting points for antimalarial lead identification. Nature, 2010, 465(7296), 305-310.
8. WHO. Press Release. WHO urges countries to act on new antiresistance malaria medicines. 25-4-2002.
9. WHO. WHO World Malaria Report 2011, 2011.
10. Tjitra, E.; Anstey, N. M.; Sugiarto, P.; Warikar, N.; Kenangalem, E.; Karyana, M.; Lampah, D. A.; Price, R. N. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS. Med., 2008, 5(6), e128.
11. Chen, L. H.; Wilson, M. E.; Schlagenhauf, P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA, 2007, 297(20), 2251-2263.
12. Coppel, R. L.; Roos, D. S.; Bozdech, Z. The genomics of malaria infection. Trend. Parasitol., 2004, 20(12), 553-557.
13. Rottmann, M.; McNamara, C.; Yeung, B. K.; Lee, M. C.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; Gonzalez-Paez, G. E.; Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H. P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; Fidock, D. A.; Winzeler, E. A.; Diagana, T. T. Spiroindolones, a potent compound class for the treatment of malaria. Science, 2010, 329(5996), 1175-1180.
14. Meister, S.; Plouffe, D. M.; Kuhen, K. L.; Bonamy, G. M.; Wu, T.; Barnes, S. W.; Bopp, S. E.; Borboa, R.; Bright, A. T.; Che, J.; Cohen, S.; Dharia, N. V.; Gagaring, K.; Gettayacamin, M.; Gordon, P.; Groessl, T.; Kato, N.; Lee, M. C.; McNamara, C. W.; Fidock, D. A.; Nagle, A.; Nam, T. G.; Richmond, W.; Roland, J.; Rottmann, M.; Zhou, B.; Froissard, P.; Glynne, R. J.; Mazier, D.; Sattabongkot, J.; Schultz, P. G.; Tuntland, T.; Walker, J. R.; Zhou, Y.; Chatterjee, A.; Diagana, T. T.; Winzeler, E. A. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science, 2011, 334(6061), 1372-1377.
15. Sa, J. M.; Twu, O. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type. Malar. J., 2010, 9, 374.
16. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. 22-11-2010. 6-6-2011.
17. White, N. J. Antimalarial drug resistance. J. Clin. Invest., 2004, 113(8), 1084-1092.
18. Smith, D. L.; Klein, E. Y.; McKenzie, F. E.; Laxminarayan, R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar. J., 2010, 9, 217.
19. Boni, M. F.; Buckee, C. O.; White, N. J. Mathematical models for a new era of malaria eradication. PLoS Med., 2008, 5(11), e231.
20. Boni, M. F.; Buckee, C. O.; White, N. J. Mathematical models for a new era of malaria eradication. PLoS Med., 2008, 5(11), e231.
21. Plowe, C. V.; Alonso, P. L.; Kremsner, P.; Magill, A.; Nájera, J. A research agenda for malaria eradication: drugs. PLoS Med., 2011, 8(1).
22. Agnandji, S. T.; Lell, B.; Soulanoudjingar, S. S.; Fernandes, J. F.; Abossolo, B. P.; Conzelmann, C.; Methogo, B. G.; Doucka, Y.; Flamen, A.; Mordmuller, B.; Issifou, S.; Kremsner, P. G.; Sacarlal, J.; Aide, P.; Lanaspa, M.; Aponte, J. J.; Nhamuave, A.; Quelhas, D.; Bassat, Q.; Mandjate, S.; Macete, E.; Alonso, P.; Abdulla, S.; Salim, N.; Juma, O.; Shomari, M.; Shubis, K.; Machera, F.; Hamad, A. S.; Minja, R.; Mtoro, A.; Sykes, A.; Ahmed, S.; Urassa, A. M.; Ali, A. M.; Mwangoka, G.; Tanner, M.; Tinto, H.; D'Alessandro, U.; Sorgho, H.; Valea, I.; Tahita, M. C.; Kabore, W.; Ouedraogo, S.; Sandrine, Y.; Guiguemde, R. T.; Ouedraogo, J. B.; Hamel, M. J.; Kariuki, S.; Odero, C.; Oneko, M.; Otieno, K.; Awino, N.; Omoto, J.; Williamson, J.; Muturi-Kioi, V.; Laserson, K. F.; Slutsker, L.; Otieno, W.; Otieno, L.; Nekoye, O.; Gondi, S.; Otieno, A.; Ogutu, B.; Wasuna, R.; Owira, V.; Jones, D.; Onyango, A. A.; Njuguna, P.; Chilengi, R.; Akoo, P.; Kerubo, C.; Gitaka, J.; Maingi, C.; Lang, T.; Olotu, A.; Tsofa, B.; Bejon, P.; Peshu, N.; Marsh, K.; Owusu-Agyei, S.; Asante, K. P.; Osei-Kwakye, K.; Boahen, O.; Ayamba, S.; Kayan, K.; Owusu-Ofori, R.; Dosoo, D.; Asante, I.; Adjei, G.; Adjei, G.; Chandramohan, D.; Greenwood, B.; Lusingu, J.; Gesase, S.; Malabeja, A.; Abdul, O.; Kilavo, H.; Mahende, C.; Liheluka, E.; Lemnge, M.; Theander, T.; Drakeley, C.; Ansong, D.; Agbenyega, T.; Adjei, S.; Boateng, H. O.; Rettig, T.; Bawa, J.; Sylverken, J.; Sambian, D.; Agyekum, A.; Owusu, L.; Martinson, F.; Hoffman, I.; Mvalo, T.; Kamthunzi, P.; Nkomo, R.; Msika, A.; Jumbe, A.; Chome, N.; Nyakuipa, D.; Chintedza, J.; Ballou, W. R.; Bruls, M.; Cohen, J.; Guerra, Y.; Jongert, E.; Lapierre, D.; Leach, A.; Lievens, M.; Ofori-Anyinam, O.; Vekemans, J.; Carter, T.; Leboulleux, D.; Loucq, C.; Radford, A.; Savarese, B.; Schellenberg, D.; Sillman, M.; Vansadia, P. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med., 2011, 365(20), 1863-1875.
23. Penny, M. A.; Maire, N.; Studer, A.; Schapira, A.; Smith, T. A. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS. One, 2008, 3(9), e3193.
24. Wells, T. N.; Burrows, J. N.; Baird, J. K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trend. Parasitol., 2010, 26(3), 145-151.
25. Dembele, L.; Gego, A.; Zeeman, A. M.; Franetich, J. F.; Silvie, O.; Rametti, A.; Le, G. R.; Dereuddre-Bosquet, N.; Sauerwein, R.; van Gemert, G. J.; Vaillant, J. C.; Thomas, A. W.; Snounou, G.; Kocken, C. H.; Mazier, D. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS. One, 2011, 6(3), e18162.
26. Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov., 2009, 8(11), 879-891.
27. Poravuth, Y.; Socheat, D.; Rueangweerayut, R.; Uthaisin, C.; Pyae, P. A.; Valecha, N.; Rao, B. H.; Tjitra, E.; Purnama, A.; Borghini-Fuhrer, I.; Duparc, S.; Shin, C. S.; Fleckenstein, L. Pyronaridineartesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS. One, 2011, 6(1), e14501.
28. WHO. Assessment of the safety of artemisinin compounds in pregnancy. 2007. 12-5-2011.
29. WHO. World Malaria Report 2010. 2010. 6-6-2011.
30. Brewer, T. G.; Peggins, J. O.; Grate, S. J.; Petras, J. M.; Levine, B. S.; Weina, P. J.; Swearengen, J.; Heiffer, M. H.; Schuster, B. G. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg., 1994, 88 Suppl 1, S33-S36.
31. Tsui, A.; Lee. M. A. Multiple sclerosis and pregnancy. Curr. Opin. Obstet. Gynecol., 2011, 23(6), 435-439.
32. Østensen, M.; Villiger, P. M.; Förger, F. Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun. Rev., 2012, 11(6-7), 437-446.
33. Manyando, C.; Mkandawire, R.; Puma, L.; Sinkala, M.; Mpabalwani, E.; Njunju, E.; Gomes, M.; Ribeiro, I.; Walter, V.; Virtanen, M.; Schlienger, R.; Cousin, M.; Chipimo, M.; Sullivan, F. M. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar. J., 2010, 9, 249.
34. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6(1), 29-40.
35. Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.; Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S. S.; Yeung, S.; Singhasivanon, P.; Day, N. P.; Lindegardh, N.; Socheat, D.; White, N. J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 2009, 361(5), 455-467.
36. Enserink, M. Malaria's drug miracle in danger. Science, 2010, 328(5980), 844-846.
37. Krishna, S.; Woodrow, C.; Webb, R.; Penny, J.; Takeyasu, K.; Kimura, M.; East, J. M. Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J. Biol. Chem., 2001, 276(14), 10782-10787.
38. Wu, T.; Nagle, A.; Kuhen, K.; Gagaring, K.; Borboa, R.; Francek, C.; Chen, Z.; Plouffe, D.; Goh, A.; Lakshminarayana, S. B.; Wu, J.; Ang, H. Q.; Zeng, P.; Kang, M. L.; Tan, W.; Tan, M.; Ye, N.; Lin, X.; Caldwell, C.; Ek, J.; Skolnik, S.; Liu, F.; Wang, J.; Chang, J.; Li, C.; Hollenbeck, T.; Tuntland, T.; Isbell, J.; Fischli, C.; Brun, R.; Rottmann, M.; Dartois, V.; Keller, T.; Diagana, T.; Winzeler, E.; Glynne, R.; Tully, D. C.; Chatterjee, A. K. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. Chem., 2011, 54(14), 5116-5130.
39. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El, M. F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jimenez-Diaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem., 2011, 54(15), 5540-5561.
40. Charman, S. A.; Arbe-Barnes, S.; Bathurst, I. C.; Brun, R.; Campbell, M.; Charman, W. N.; Chiu, F. C.; Chollet, J.; Craft, J. C.; Creek, D. J.; Dong, Y.; Matile, H.; Maurer, M.; Morizzi, J.; Nguyen, T.; Papastogiannidis, P.; Scheurer, C.; Shackleford, D. M.; Sriraghavan, K.; Stingelin, L.; Tang, Y.; Urwyler, H.; Wang, X.; White, K. L.; Wittlin, S.; Zhou, L.; Vennerstrom, J. L. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. USA, 2011, 108(11), 4400-4405.
41. MMV Annual Report 2010, 2011.
42. Mital, A. Recent advances in antimalarial compounds and their patents. Curr. Med. Chem., 2007, 14(7), 759-773.
43. Monzote, L. A review of anti-parasitic patents (1988-2008). Recent Pat. Antiinfect. Drug Discov., 2008, 3(3), 177-191.
44. Gemma, S.; Travagli, V.; Savini, L.; Novellino, E.; Campiani, G.; Butini, S. Malaria chemotherapy: recent advances in drug development. Recent Pat. Antiinfect. Drug Discov., 2010, 5(3), 195-225.
45. Muraleedharan, K. M.; Avery, M. A. Progress in the development of peroxide-based anti-parasitic agents. Drug Discov. Today, 2009, 14(15-16), 793-803.
46. Oldfield, E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc. Chem. Res., 2010, 43(9), 1216-1226.
47. Andrews, K. T.; Tran, T. N.; Wheatley, N. C.; Fairlie, D. P. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem., 2009, 9(3), 292-308.
48. Yeates, C. L.; Batchelor, J. F.; Capon, E. C.; Cheesman, N. J.; Fry, M.; Hudson, A. T.; Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J. M.; Chicharro, J.; Fernandez, E.; Fiandor, J. M.; Gargallo-Viola, D.; Gomez de las, H. F.; Herreros, E.; Leon, M. L. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. Med. Chem., 2008, 51(9), 2845-2852.
49. Still, J. G.; Schranz, J.; Degenhardt, T. P.; Scott, D.; Fernandes, P.; Gutierrez, M. J.; Clark, K. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on singledose bioavailability in healthy adult subjects. Antimicrob. Agents Ch., 2011, 55(5), 1997-2003.
50. Beghdadi, W.; Porcherie, A.; Schneider, B. S.; Dubayle, D.; Peronet, R.; Huerre, M.; Watanabe, T.; Ohtsu, H.; Louis, J.; Mecheri, S. Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease. J. Exp. Med., 2008, 205(2), 395-408.
51. Zhang, Y. K.; Plattner, J. J.; Freund, Y. R.; Easom, E. E.; Zhou, Y.; Gut, J.; Rosenthal, P. J.; Waterson, D.; Gamo, F. J.; Angulo-Barturen, I.; Ge, M.; Li, Z.; Li, L.; Jian, Y.; Cui, H.; Wang, H.; Yang, J. Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents. Bio. Org. Med. Chem. Lett., 2011, 21(2), 644-651.
52. Parroche, P.; Lauw, F. N.; Goutagny, N.; Latz, E.; Monks, B. G.; Visintin, A.; Halmen, K. A.; Lamphier, M.; Olivier, M.; Bartholomeu, D. C.; Gazzinelli, R. T.; Golenbock, D. T. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci., USA, 2007, 104(6), 1919-1924.
53. Wells, T. N. Natural products as starting points for future antimalarial therapies: going back to our roots? Malar. J., 2011, 10 Suppl 1, S3.
54. Mboya-Okeyo, T.; Ridley, R. G.; Nwaka, S. The african network for drugs and diagnostics innovation. Lancet, 2009, 373(9674), 1507-1508.
55. Breman, J. G.; de Quadros, C. A.; Dowdle, W. R.; Foege, W. H.; Henderson, D. A.; John, T. J.; Levine, M. M. The role of research in viral disease eradication and elimination programs: lessons for malaria eradication. PLoS Med., 2011, 8(1), e1000405.